CL:0002087

Name:	nongranular leukocyte
Namespace:	FANTOM
Definition:	"A leukocyte that lacks granules." [GOC:tfm]
Xrefs:	Expandlinks: FMA:62855
Synonyms:	"agranular leukocyte" EXACT []
Created by:	tmeehan
Creation date:	2010-07-22T11:30:33Z

Ontology association <br>Each term has an is_a parent in the Cell ontology, which has a linkage to an another entity and FANTOM5 samples.Libraries were grouped into mutually exclusive facets according to the FANTOM5 sample ontology mapping to Cell ontologies.<br><br>link to ontology dataset<br>data

---

Parents

is_a:	CL:0000738(leukocyte)

Children

is a:	CL:0000542 (lymphocyte),CL:0000576 (monocyte),CL:0000842 (mononuclear cell)

Ontology Tree: Loaded from BioPortal

Ontorolgy tree(Small window open)

FF samples<br>It includes FANTOM5 samples that overlay the Cell ontology.

---

Human (Homo sapiens)

• 10399-106A3 (acute myeloid leukemia (FAB M5) cell line:THP-1 (fresh))
• 10400-106A4 (acute myeloid leukemia (FAB M5) cell line:THP-1 (revived))
• 10405-106A9 (acute myeloid leukemia (FAB M5) cell line:THP-1 (thawed))
• 10416-106C2 (chronic lymphocytic leukemia (T-CLL) cell line:SKW-3)
• 10421-106C7 (adult T-cell leukemia cell line:ATN-1)
• 10422-106C8 (Burkitt's lymphoma cell line:DAUDI)
• 10427-106D4 (b cell line:RPMI1788)
• 10429-106D6 (acute lymphoblastic leukemia (T-ALL) cell line:HPB-ALL)
• 10455-106G5 (acute lymphoblastic leukemia (B-ALL) cell line:BALL-1)
• 10464-106H5 (acute lymphoblastic leukemia (T-ALL) cell line:Jurkat)

... further results Mouse (Mus musculus)

• 10399-106A3 (acute myeloid leukemia (FAB M5) cell line:THP-1 (fresh))
• 10400-106A4 (acute myeloid leukemia (FAB M5) cell line:THP-1 (revived))
• 10405-106A9 (acute myeloid leukemia (FAB M5) cell line:THP-1 (thawed))
• 10416-106C2 (chronic lymphocytic leukemia (T-CLL) cell line:SKW-3)
• 10421-106C7 (adult T-cell leukemia cell line:ATN-1)
• 10422-106C8 (Burkitt's lymphoma cell line:DAUDI)
• 10427-106D4 (b cell line:RPMI1788)
• 10429-106D6 (acute lymphoblastic leukemia (T-ALL) cell line:HPB-ALL)
• 10455-106G5 (acute lymphoblastic leukemia (B-ALL) cell line:BALL-1)
• 10464-106H5 (acute lymphoblastic leukemia (T-ALL) cell line:Jurkat)

... further results

Enrichment analysis: top 100 FFCP enriched with this ontology termTOP 100 FANTOM5 Cage Peaks enriched with CL:0002087 (nongranular leukocyte), sorted by p-values <br>Analyst: Hideya Kawaji<br><br>link to source dataset <br>human : data <br>mouse : data

---

Copy Excel CSV PDF

Search:

P-value	FFCP	Short description

P-value	FFCP	Short description
6.22e-105	FFCP PHASE2:Hg19::chr14:100531693..100531705,+	p6@EVL
6.22e-105	FFCP PHASE1:Hg19::chr14:100531693..100531705,+	p6@EVL
3.55e-98	FFCP PHASE2:Hg19::chr14:100531713..100531724,+	p11@EVL
3.55e-98	FFCP PHASE1:Hg19::chr14:100531713..100531724,+	p11@EVL
5.93e-97	FFCP PHASE1:Hg19::chr1:160681573..160681587,-	p2@CD48
5.93e-97	FFCP PHASE2:Hg19::chr1:160681573..160681587,-	p2@CD48
7.03e-95	FFCP PHASE2:Hg19::chr19:49842010..49842054,+	p@chr19:49842010..49842054, +
7.03e-95	FFCP PHASE1:Hg19::chr19:49842010..49842054,+	p@chr19:49842010..49842054, +
1.93e-94	FFCP PHASE1:Hg19::chr1:27952741..27952753,-	p8@FGR
1.93e-94	FFCP PHASE2:Hg19::chr1:27952741..27952753,-	p8@FGR
2.5e-94	FFCP PHASE2:Hg19::chr2:24149046..24149063,+	p@chr2:24149046..24149063, +
2.5e-94	FFCP PHASE1:Hg19::chr2:24149046..24149063,+	p@chr2:24149046..24149063, +
2.6e-94	FFCP PHASE2:Hg19::chr21:46340884..46340893,-	p3@ITGB2
2.6e-94	FFCP PHASE1:Hg19::chr21:46340884..46340893,-	p3@ITGB2
1.47e-92	FFCP PHASE1:Hg19::chr16:50776625..50776663,-	p@chr16:50776625..50776663, -
1.47e-92	FFCP PHASE2:Hg19::chr16:50776625..50776663,-	p@chr16:50776625..50776663, -
2.81e-92	FFCP PHASE2:Hg19::chr1:209941862..209941887,+	p6@TRAF3IP3
2.81e-92	FFCP PHASE1:Hg19::chr1:209941862..209941887,+	p6@TRAF3IP3
1.71e-91	FFCP PHASE2:Hg19::chr1:27952755..27952769,-	p9@FGR
1.71e-91	FFCP PHASE1:Hg19::chr1:27952755..27952769,-	p9@FGR
2.63e-91	FFCP PHASE2:Hg19::chr1:9711821..9711832,+	p2@PIK3CD
2.63e-91	FFCP PHASE1:Hg19::chr1:9711821..9711832,+	p2@PIK3CD
2.95e-91	FFCP PHASE1:Hg19::chr19:49842573..49842602,+	p@chr19:49842573..49842602, +
2.95e-91	FFCP PHASE2:Hg19::chr19:49842573..49842602,+	p@chr19:49842573..49842602, +
3.26e-91	FFCP PHASE1:Hg19::chr1:241695424..241695440,+	p2@KMO
3.26e-91	FFCP PHASE2:Hg19::chr1:241695424..241695440,+	p2@KMO
1.05e-90	FFCP PHASE1:Hg19::chr19:18197799..18197815,-	p2@IL12RB1
1.05e-90	FFCP PHASE2:Hg19::chr19:18197799..18197815,-	p2@IL12RB1
1.13e-90	FFCP PHASE2:Hg19::chr2:158300487..158300500,-	p3@CYTIP
1.13e-90	FFCP PHASE1:Hg19::chr2:158300487..158300500,-	p3@CYTIP
5.51e-89	FFCP PHASE1:Hg19::chr5:149790235..149790248,-	p@chr5:149790235..149790248, -
5.51e-89	FFCP PHASE2:Hg19::chr5:149790235..149790248,-	p@chr5:149790235..149790248, -
1.29e-88	FFCP PHASE1:Hg19::chr1:203256483..203256503,-	p@chr1:203256483..203256503, -
1.29e-88	FFCP PHASE2:Hg19::chr1:203256483..203256503,-	p@chr1:203256483..203256503, -
1.62e-88	FFCP PHASE2:Hg19::chr2:145276968..145276984,+	p1@ZEB2-AS1
1.62e-88	FFCP PHASE1:Hg19::chr2:145276968..145276984,+	p1@ZEB2-AS1
3.1e-88	FFCP PHASE2:Hg19::chr19:49843537..49843640,+	p@chr19:49843537..49843640, +
3.1e-88	FFCP PHASE1:Hg19::chr19:49843537..49843640,+	p@chr19:49843537..49843640, +
4.19e-88	FFCP PHASE2:Hg19::chr19:49838937..49838974,+	p@chr19:49838937..49838974, +
4.19e-88	FFCP PHASE1:Hg19::chr19:49838937..49838974,+	p@chr19:49838937..49838974, +
1.33e-87	FFCP PHASE1:Hg19::chr2:68592394..68592405,+	p2@PLEK
1.33e-87	FFCP PHASE2:Hg19::chr2:68592394..68592405,+	p2@PLEK
2.52e-87	FFCP PHASE1:Hg19::chr1:206730535..206730549,+	p4@RASSF5
2.52e-87	FFCP PHASE2:Hg19::chr1:206730535..206730549,+	p4@RASSF5
2.56e-87	FFCP PHASE1:Hg19::chr22:18260077..18260127,+	p1@LINC00528
2.56e-87	FFCP PHASE2:Hg19::chr22:18260077..18260127,+	p1@LINC00528
3.44e-87	FFCP PHASE2:Hg19::chr19:16695359..16695379,+	p@chr19:16695359..16695379, +
3.44e-87	FFCP PHASE1:Hg19::chr19:16695359..16695379,+	p@chr19:16695359..16695379, +
4.03e-87	FFCP PHASE1:Hg19::chr18:48405033..48405061,+	p3@ME2
4.03e-87	FFCP PHASE2:Hg19::chr18:48405033..48405061,+	p3@ME2
7.88e-87	FFCP PHASE2:Hg19::chr2:231090471..231090504,+	p2@SP140
7.88e-87	FFCP PHASE1:Hg19::chr2:231090471..231090504,+	p2@SP140
1.02e-86	FFCP PHASE2:Hg19::chr2:163175430..163175460,-	p2@IFIH1
1.02e-86	FFCP PHASE1:Hg19::chr2:163175430..163175460,-	p2@IFIH1
1.64e-86	FFCP PHASE1:Hg19::chr1:31206575..31206590,-	p@chr1:31206575..31206590, -
1.64e-86	FFCP PHASE2:Hg19::chr1:31206575..31206590,-	p@chr1:31206575..31206590, -
2.42e-86	FFCP PHASE2:Hg19::chr15:73075463..73075507,+	p1@LOC100287559
2.42e-86	FFCP PHASE1:Hg19::chr15:73075463..73075507,+	p1@LOC100287559
2.44e-86	FFCP PHASE1:Hg19::chr10:114134954..114135003,+	p5@ACSL5
2.44e-86	FFCP PHASE2:Hg19::chr10:114134954..114135003,+	p5@ACSL5
3.68e-86	FFCP PHASE1:Hg19::chr6:32577619..32577667,-	p@chr6:32577619..32577667, -
3.68e-86	FFCP PHASE2:Hg19::chr6:32577619..32577667,-	p@chr6:32577619..32577667, -
6.68e-86	FFCP PHASE2:Hg19::chr6:32411527..32411547,+	p4@HLA-DRA
6.68e-86	FFCP PHASE1:Hg19::chr6:32411527..32411547,+	p4@HLA-DRA
1.09e-85	FFCP PHASE1:Hg19::chr19:2085302..2085320,-	p3@MOB3A
1.09e-85	FFCP PHASE2:Hg19::chr19:2085302..2085320,-	p3@MOB3A
1.76e-85	FFCP PHASE1:Hg19::chr12:9801099..9801138,+	p5@LOC374443
1.76e-85	FFCP PHASE2:Hg19::chr12:9801099..9801138,+	p5@LOC374443
4.61e-85	FFCP PHASE2:Hg19::chr21:46340976..46341000,+	p1@ENST00000441379, p1@uc002zgh.2
4.61e-85	FFCP PHASE1:Hg19::chr21:46340976..46341000,+	p1@ENST00000441379, p1@uc002zgh.2
5.83e-85	FFCP PHASE1:Hg19::chr6:33036875..33036943,-	p@chr6:33036875..33036943, -
5.83e-85	FFCP PHASE2:Hg19::chr6:33036875..33036943,-	p@chr6:33036875..33036943, -
4.54e-84	FFCP PHASE2:Hg19::chr1:198668673..198668721,+	p@chr1:198668673..198668721, +
4.54e-84	FFCP PHASE1:Hg19::chr1:198668673..198668721,+	p@chr1:198668673..198668721, +
4.69e-84	FFCP PHASE1:Hg19::chr1:161039753..161039765,-	p5@ARHGAP30
4.69e-84	FFCP PHASE2:Hg19::chr1:161039753..161039765,-	p5@ARHGAP30
5.1e-84	FFCP PHASE1:Hg19::chr6:32412417..32412458,+	p@chr6:32412417..32412458, +
5.1e-84	FFCP PHASE2:Hg19::chr6:32412417..32412458,+	p@chr6:32412417..32412458, +
7.27e-84	FFCP PHASE2:Hg19::chr2:158300517..158300544,-	p2@CYTIP
7.27e-84	FFCP PHASE1:Hg19::chr2:158300517..158300544,-	p2@CYTIP
8.77e-84	FFCP PHASE1:Hg19::chr6:36973449..36973454,+	p4@FGD2
8.77e-84	FFCP PHASE2:Hg19::chr6:36973449..36973454,+	p4@FGD2
1.85e-83	FFCP PHASE2:Hg19::chrX:48547205..48547222,+	p2@WAS
1.85e-83	FFCP PHASE1:Hg19::chrX:48547205..48547222,+	p2@WAS
1.97e-83	FFCP PHASE1:Hg19::chr6:33037019..33037047,-	p5@HLA-DPA1
1.97e-83	FFCP PHASE2:Hg19::chr6:33037019..33037047,-	p5@HLA-DPA1
3.03e-83	FFCP PHASE2:Hg19::chr9:74920462..74920487,+	p1@ENST00000451152
3.03e-83	FFCP PHASE1:Hg19::chr9:74920462..74920487,+	p1@ENST00000451152
3.58e-83	FFCP PHASE1:Hg19::chr15:45018966..45018983,-	p@chr15:45018966..45018983, -
3.58e-83	FFCP PHASE2:Hg19::chr15:45018966..45018983,-	p@chr15:45018966..45018983, -
3.99e-83	FFCP PHASE1:Hg19::chr6:159465957..159465968,-	p3@TAGAP
3.99e-83	FFCP PHASE2:Hg19::chr6:159465957..159465968,-	p3@TAGAP
4.17e-83	FFCP PHASE1:Hg19::chr19:1067256..1067270,+	p4@HMHA1
4.17e-83	FFCP PHASE2:Hg19::chr19:1067256..1067270,+	p4@HMHA1
4.94e-83	FFCP PHASE2:Hg19::chr7:38389667..38389687,+	p1@M27346
4.94e-83	FFCP PHASE1:Hg19::chr7:38389667..38389687,+	p1@M27346
7.34e-83	FFCP PHASE1:Hg19::chr1:209941889..209941928,+	p2@TRAF3IP3
7.34e-83	FFCP PHASE2:Hg19::chr1:209941889..209941928,+	p2@TRAF3IP3
9.65e-83	FFCP PHASE1:Hg19::chr2:128458939..128458961,-	p@chr2:128458939..128458961, -
9.65e-83	FFCP PHASE2:Hg19::chr2:128458939..128458961,-	p@chr2:128458939..128458961, -

Showing 1 to 100 of 100 entries